I have no disclosures relevant to this lecture to report.
Pre-surgical Considerations

- Psychosocial factors affecting access to CT TX and MCS
- Patient preferences and decision-making
- Psychosocial evaluation for CT TX and MCS implant
- Informed consent

CT TX and MCS Surgery

Psychosocial Outcomes During CT TX and MCS Implant

- Patient physical, psychological, social, and global HRQOL
- Patient adherence and self-care
- Family caregiver well-being and QOL
- Economic burdens for the patient and family

Psychosocial Predictors of Clinical Outcomes During CT TX and MCS

- Adverse events
- Survival

Post-operative and End of Life Considerations

- Post-operative Outcomes
  - Patient HRQOL after surgery
  - Patient HRQOL after recovery

End of Life Issues

- Patient preferences and decision-making
- Family concerns
- Symptom management and palliative care choices

CT = cardiothoracic; TX = transplant; MCS = mechanical circulatory support; HRQOL = health-related quality of life

Grady KL & Dew MA, from Braunwald E, MCS Companion to Heart Disease, 2017 (modified)
### Psychosocial factors at each stage of the transplant & mechanical circulatory support process

#### Pre-surgical Considerations
- Psychosocial factors affecting access to CT TX and MCS
- Patient preferences and decision-making
- Psychosocial evaluation for CT TX and MCS implant
- Informed consent

#### CT TX and MCS Surgery

#### Psychosocial Outcomes During CT TX and MCS Implant
- Patient physical, psychological, social, and global HRQOL
- Patient adherence and self-care
- Family caregiver well-being and QOL
- Economic burdens for the patient and family

#### Psychosocial Predictors of Clinical Outcomes During CT TX and MCS
- Adverse events
- Survival

#### Post-operative and End of Life Considerations
- Post-operative Outcomes
  - Patient HRQOL after surgery
  - Patient HRQOL after recovery
- End of Life Issues
  - Patient preferences and decision-making
  - Family concerns
  - Symptom management and palliative care choices

---

CT = cardiothoracic; TX = transplant; MCS = mechanical circulatory support; HRQOL = health-related quality of life

*Grady KL & Dew MA, from Braunwald E, MCS Companion to Heart Disease, 2017 (modified)*
Access to Care

• Race and sex disparities in receipt of CT TX and MCS stem from multiple factors
  – referral practices and biases
  – uneven application of evidence-based guidelines for care
  – patient preferences for care

• There is growing evidence that interventions that facilitate care provider adherence to clinical practice guidelines can reduce disparities in treatments offered to patients.
HT in Women with Dilated Cardiomyopathy

- Single-center German study
  (n=698 DCM pts referred to HT center [15.5% female])

- Women vs men more frequently:
  - NYHA III-IV
  - ↓ exercise tolerance
  - worse pulmonary and kidney function

- Referral for HT:
  - Women=16%
  - Men=84%

- Listing for HT:
  - Women=43%
  - Men=41%

- HT among listed patients:
  - Women=61% / 24% died
  - Men=55% / 33% died

Regitz-Zagrosel V, et al., Clin & Translational Res 2010
HT in Women with Dilated Cardiomyopathy

- Single-center German study
  (n=698 DCM pts referred to HT center [15.5% female])

- Women vs men more frequently:
  - NYHA III-IV
  - ↓ exercise tolerance
  - worse pulmonary and kidney function

- Referral for HT:
  - Women=16%
  - Men=84%

- Listing for HT:
  - Women=43%
  - Men=41%

- HT among listed patients:
  - Women=61% / 24% died
  - Men=55% / 33% died

Regitz-Zagrosel V, et al., Clin & Translational Res 2010
Why were Female Referral Rates Lower?

- Single center U.S. study (Aaronson KD, 1995)
  - n=386 pts referred for management of mod-severe HF and/or HT evaluation
- Female gender was associated with not being accepted for HT (odds ratio, 2.57, p=0.01)
- Reason for not being accepted:
  - mostly self-refusal: women (29%) vs men (9%)
- Other reasons for non acceptance:
  - lower patient income (Aaronson KD et al)
  - lower social support in women than men (Regitz-Zagrosek V et al.)
**Psychosocial factors at each stage of the transplant & mechanical circulatory support process**

**Pre-surgical Considerations**
- Psychosocial factors affecting access to CT TX and MCS
- Patient preferences and decision-making
- Psychosocial evaluation for CT TX and MCS implant
- Informed consent

**CT TX and MCS Surgery**

**Psychosocial Outcomes During CT TX and MCS Implant**
- Patient physical, psychological, social, and global HRQOL
- Patient adherence and self-care
- Family caregiver well-being and QOL
- Economic burdens for the patient and family

**Psychosocial Predictors of Clinical Outcomes During CT TX and MCS**
- Adverse events
- Survival

**Post-operative and End of Life Considerations**
- Post-operative Outcomes
  - Patient HRQOL after surgery
  - Patient HRQOL after recovery

**End of Life Issues**
- Patient preferences and decision-making
- Family concerns
- Symptom management and palliative care choices

CT = cardiothoracic; TX= transplant; MCS = mechanical circulatory support; HRQOL = health-related quality of life

Grady KL & Dew MA, from Braunwald E, MCS Companion to Heart Disease, 2017 (modified)
• Risks and benefits are presented when clinicians and patients **together** consider treatment options
Shared Decision Making Incorporates Patient-centered Care

Equitable  
Patient-centered

Effective  Safe  Timely  Efficient

Shared Decision Making Incorporates Patient-centered Care

• Respectful of and responsive to individual patient preferences, needs, values, and goals which guide all clinical decisions.

• Consistent with current professional knowledge AND includes a discussion of desired patient health outcomes.

Institute of Medicine. Crossing the Quality Chasm: A New Healthcare System for the 21st Century
Shared decision making and mechanical circulatory support implantation

- **Interviewer:** “Do you have any expectations regarding the VAD”?
- **Interviewee:** “… I will feel better and the main thing is it will help keep me alive, so that is also an incentive”.

- **Interviewer:** “What are your expectations in terms of getting the VAD”?
- **Interviewee:** “Really for me it is kind of simple things like I can walk, I can go to basketball games and football games climb a couple of bleachers; just do some things with my wife. I like to go shopping with her and we pretty much do a lot of things together anyway but when I go now she shops and I find a place to sit”.

Grady K, et al., AHA grant-in-aid 2012-2014
What Outcomes do Patients Care About?

Outcomes relevant to an individual patient

- Survival
- Costs / Burden
- Quality of life

Adult Heart Transplants
Kaplan-Meier Survival by Era
(Transplants: January 1982 – June 2016)

Median survival (years):

All pair-wise comparisons were significant at p < 0.0001.
Actuarial survival for primary device implant, stratified by device type. Error bars indicate ± 1 SE. Patients are censored at transplant and recovery. CF, continuous flow; LVAD, left ventricular assist device; PF, pulsatile flow; TAH, total artificial heart.

Satisfaction with Quality of Life at 5-10 Years after Heart Transplantation

* based on a scale of 0-1; 0=least satisfied, 1=most satisfied
HRQOL after VAD implant
EQ-5D Visual Analog Scale

INTERMACS Patient Profile Levels

Utilizes all EQ-5D data available at each time period; too sick assigned “0”

Grady K, et al. JHLT, 2013

p < .0001 comparing all profiles pre implant
p = .0005 comparing all profiles at 3 months post implant
0.27 comparing all profiles at 6 months post implant
0.39 comparing all profiles at 12 months post implant
“I think that the lived experience of spouses providing care to patients with a left ventricular assist device (LVAD)… is under appreciated by healthcare professionals, and the outcomes of this situation are not obvious.”

Barletti MH. Editorial, AJCC 2005:14; 143-144.
**Caregiver Burden**

<table>
<thead>
<tr>
<th>Four major domains of burden:</th>
<th>HT</th>
<th>VAD</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Task performance</td>
<td>↑</td>
<td>↑↑</td>
</tr>
<tr>
<td>• Time constraints</td>
<td>↑</td>
<td>↑↑</td>
</tr>
<tr>
<td>• Worry about patient health</td>
<td>↓</td>
<td>↑↓</td>
</tr>
<tr>
<td>• Financial burden</td>
<td>↑↑</td>
<td>↑↑</td>
</tr>
</tbody>
</table>
## Psychosocial factors at each stage of the transplant & mechanical circulatory support process

<table>
<thead>
<tr>
<th>Pre-surgical Considerations</th>
<th>Psychosocial Outcomes During CT TX and MCS Implant</th>
<th>Post-operative and End of Life Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychosocial factors affecting access to CT TX and MCS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient preferences and decision-making</td>
<td>Patient physical, psychological, social, and global HRQOL</td>
<td>Post-operative Outcomes</td>
</tr>
<tr>
<td>Psychosocial evaluation for CT TX and MCS implant</td>
<td>Patient adherence and self-care</td>
<td>Patient HRQOL after surgery</td>
</tr>
<tr>
<td>Informed consent</td>
<td>Family caregiver well-being and QOL</td>
<td>Patient HRQOL after recovery</td>
</tr>
<tr>
<td></td>
<td>Economic burdens for the patient and family</td>
<td></td>
</tr>
</tbody>
</table>

### CT TX and MCS Surgery

<table>
<thead>
<tr>
<th>Psychosocial Predictors of Clinical Outcomes During CT TX and MCS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse events</td>
</tr>
<tr>
<td>Survival</td>
</tr>
</tbody>
</table>

### End of Life Issues

<table>
<thead>
<tr>
<th>Patient preferences and decision-making</th>
</tr>
</thead>
<tbody>
<tr>
<td>Family concerns</td>
</tr>
<tr>
<td>Symptom management and palliative care choices</td>
</tr>
</tbody>
</table>

CT = cardiothoracic; TX= transplant; MCS = mechanical circulatory support; HRQOL = health-related quality of life

*Grady KL & Dew MA, from Braunwald E, MCS Companion to Heart Disease, 2017 (modified)*
Need for Psychosocial Evaluation

• Pre-transplant psychosocial factors predict outcomes after cardiothoracic transplantation
  – patients’ history of medical adherence
  – mental health
  – substance use
  – social support

• Outcomes include
  – transplant-related morbidities
  – mortality
  – medical adherence
  – quality of life (QOL)
Value of Psychosocial Evaluation

Despite recognition of the value of the psychosocial evaluation by ISHLT guidelines ... issues and challenges of conducting evaluations include:

• What is the full range of psychosocial domains that should be assessed?
• What processes should be used to conduct the evaluation?
• How should findings be reported?
• What are the processes for monitoring patients’ receipt of interventions for any identified problems?
A Consensus Document

ISHLT CONSENSUS

The 2018 ISHLT/APM/AST/ICCAC/STSW recommendations for the psychosocial evaluation of adult cardiothoracic transplant candidates and candidates for long-term mechanical circulatory support

Mary Amanda Dew, PhD, Andrea F. DiMartini, MD, Fabienne Dobbels, PhD, Kathleen L. Grady, PhD, RN, Sheila G. Jowsey-Gregoire, MD, Annemarie Kaan, MCN, RN, Kay Kendall, MSW, LISW, Quincy-Robyn Young, PhD, Susan E. Abbey, MD, Zeeshan Butt, PhD, Catherine C. Crone, MD, Sabina De Geest, PhD, Christina T. Doligalski, PharmD, Christiane Kugler, PhD, Laurie McDonald, MSW, Linda Ohler, MSN, Liz Painter, MA, Michael G. Petty, PhD, CNS, Desiree Robson, BSc, RN, Thomas Schlöglhofer, BSc, Terry D. Schneekloth, MD, Jonathan P. Singer, MD, MS, Patrick J. Smith, PhD, MPH, Heike Spaderna, PhD, Jeffrey J. Teuteberg, MD, Roger D. Yusen, MD, MPH, and Paula C. Zimbres, MD.
Methods

Strategies to come to consensus:

• Synthesis of expert opinion on the **content** of the psychosocial evaluation

• Synthesis of expert opinion on the **processes and procedures** for
  – conducting the evaluation
  – reporting its results
  – implementing any additional testing or treatment

• Literature reviews of empirical evidence to support the Committee’s recommendations regarding both evaluation content / process.
Methods

Strategies to come to consensus:

• Synthesis of expert opinion on the content of the psychosocial evaluation

• Synthesis of expert opinion on the processes and procedures for (a) conducting the evaluation, (b) reporting its results, and (c) implementing any additional testing or treatment

• Literature reviews of empirical evidence to support the Committee’s recommendations regarding both evaluation content / process.
Rationale for recommendation of 10 domains:

- Assess risk factors for poor posttransplantation / postimplantation outcomes
- Collect information on factors related to patients’ knowledge, understanding, and capacity to engage in decision-making about transplantation and/or MCS
- Collect information to characterize patients’ personal, social, and environmental resources and circumstances, including factors that may mitigate the impact of any psychosocial risk factors on posttransplantation / postimplantation outcomes
- Unique to MCS candidates, evaluate patients’ knowledge about and capacity to operate the device.
**Domains**

**Risk factors for poor outcomes after surgery**

| 1. Treatment adherence and health behaviors | • Past and current level of adherence to the required medical regimen  

• Knowledge and understanding of rationale and specific requirements of the current medical regimen (e.g., medication dosing; other self-management requirements; appointments)  

• Willingness and intent to modify self-management and lifestyle behaviors to meet changing regimen requirements |
## Domains
Risk factors for poor outcomes after surgery

| 2. Mental health history       | • Past and current mood, anxiety or other disorders  
|                              | • Symptom severity and course, chronicity of symptoms  
|                              | • Receipt, adherence, and response to psychiatric treatment  
|                              | • Current or past suicidal ideation  
|                              | • Mental health history of immediate family  
| 3. Substance use history      | • Tobacco/alcohol/drug (licit and illicit) frequency, amount, etc.  
|                              | • Level of impairment to health/work/relationships, legal issues  
|                              | • Insight into problem, commitment to remain abstinent  
|                              | • Prior and any current treatment, willingness to seek treatment  
|                              | • Substance use/abuse history of immediate family  |
## Domains
Factors related to patient knowledge, understanding, capacity for decision making

<table>
<thead>
<tr>
<th>4. Cognitive status and capacity to give informed consent</th>
<th>Evidence of <strong>cognitive impairment</strong> that would compromise capacity to comprehend information and engage in decision making about treatment options</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><em>Capacity to make judgments and decisions voluntarily without undue pressure from others</em></td>
</tr>
</tbody>
</table>
### Domains

**Factors related to patient knowledge, understanding, capacity for decision making**

<table>
<thead>
<tr>
<th>5. Knowledge and understanding of current illness</th>
<th>6. Knowledge and understanding of current treatment options</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Knowledge and understanding of the <strong>causes and course of the organ disease</strong> and its impact on daily functioning</td>
<td>• Knowledge and understanding of <strong>risks and benefits of the surgical intervention</strong> under consideration</td>
</tr>
<tr>
<td>• Understanding of <strong>rationale for treatments received and inadequacy of treatments to manage symptoms/disease progression</strong></td>
<td>• Understanding of post-intervention <strong>medical regimen, self-care and lifestyle</strong> requirements</td>
</tr>
<tr>
<td>• Understanding of <strong>reasons for referral for transplant / MCS</strong></td>
<td>• <strong>Attitudes</strong> about the intervention, e.g., receptiveness; expectations; concerns; values, preferences and goals</td>
</tr>
</tbody>
</table>
## Domains

**Factors specific to patients’ personal, social, and environmental resources and circumstances**

<table>
<thead>
<tr>
<th>7. Coping with illness</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Emotional response</strong> to illness; acceptance or denial about severity of illness, prognosis and treatment options</td>
<td></td>
</tr>
<tr>
<td><strong>Coping strategies</strong> used to manage illness and its impact on daily life (e.g., problem solving strategies, reliance on others, avoidance)</td>
<td></td>
</tr>
</tbody>
</table>
### Domains

**Factors specific to patients’ personal, social, and environmental resources and circumstances**

| 8. Social support       | • Availability, and capacity of family and others to provide support
|                        | • Understanding and knowledge among family and other supports of treatment options and current care needs
|                        | • Expectations of family and other supports about care needs after intervention |
| 9. Social history       | • **Demographics** (e.g., education, religion, literacy)
|                        | • **Relationship history** (e.g., marital status, stability of relationships)
|                        | • **Employment** experience and occupation
|                        | • **Financial status** (e.g., insurance, living arrangements, dependents)
|                        | • History of legal issues
|                        | • Concurrent life stressors and history of exposure to traumatic events |
10. Knowledge about and capacity to operate MCS device

- Knowledge and understanding of basic device operation and malfunction

- Cognitive or physical limitations, that would compromise capacity to operate the device or to perceive and respond to device alarms

- Safety of the home environment for device operation (e.g., source of electricity)
Methods

Strategies to come to consensus:

• Synthesis of expert opinion on the content of the psychosocial evaluation

• Synthesis of expert opinion on the processes and procedures for (a) conducting the evaluation, (b) reporting its results, and (c) implementing any additional testing or treatment

• Literature reviews of empirical evidence to support the Committee’s recommendations regarding both evaluation content / process.
### Processes and Procedures Related to the Psychosocial Evaluation

1. **Qualifications and experience of the evaluator**

   - The evaluator should have **training** in a healthcare discipline relevant to the content of the psychosocial evaluation.
   - The evaluator should be **registered or licensed** in their discipline.
   - For individuals new to the evaluator role, **orientation** to the transplant and/or MCS program.
   - **Ongoing evaluator education and training**
## Processes and Procedures Related to the Psychosocial Evaluation

### 2. Performance of the psychosocial evaluation

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>The patient should be <strong>informed</strong> about the evaluation’s purpose and goals.</td>
</tr>
<tr>
<td></td>
<td>Conducted in a <strong>language</strong> in which the patient can engage in interactive conversation. Interpreter services should be utilized, as needed.</td>
</tr>
<tr>
<td></td>
<td>The evaluation interview should be <strong>expanded beyond a one-time meeting</strong> with the patient if complex issues are uncovered.</td>
</tr>
<tr>
<td></td>
<td>After the initial evaluation, patients who are awaiting surgery should be <strong>reevaluated at regular intervals.</strong></td>
</tr>
<tr>
<td></td>
<td>The patient should be <strong>directly interviewed</strong> when possible.</td>
</tr>
<tr>
<td></td>
<td>When the patient cannot complete the full interview or is unable to be interviewed, the evaluator should collect <strong>collateral information</strong> as possible.</td>
</tr>
<tr>
<td></td>
<td>Given that transplant and MCS teams commonly require that the patient have a <strong>primary support person</strong>, this individual should be interviewed to determine understanding of the patient’s needs and his/her willingness and ability to provide assistance.</td>
</tr>
</tbody>
</table>
3. Use of templates or checklists as adjuncts for completing the psychosocial evaluation

| 3. Use of templates or checklists as adjuncts for completing the psychosocial evaluation | The evaluator should consider routinely using a standard template or checklist that includes each element of the psychosocial evaluation. |
### Processes and Procedures
**Related to the Psychosocial Evaluation**

| 4. Screening for capacity to give informed consent | - If cognitive impairment is suspected, use of a standardized, validated screening tool should be considered.  
- The evaluator should consider whether additional steps (use of interpreter, additional education at literacy level of patient, treatment for medical conditions) are needed before capacity can be determined.  
- Formal evaluation of the patient’s capacity to make medical decisions may be needed. |
## Processes and Procedures Related to the Psychosocial Evaluation

### 5. Communication with the transplantation or MCS team about psychosocial evaluation findings

- **A written evaluation report** should be placed in the patient’s medical record.

- The report should contain a concise summary of findings (and detail as needed) and recommendations for additional testing and/or interventions.

- When psychosocial risk factors are identified, the report should state whether the risk factors can be ameliorated and, if so, recommend treatment and timing (i.e., before or after surgery).

- **Recommendations** stated in the report should take into account what is feasible.

- The report should be shared at a multidisciplinary meeting when transplant listing decisions or MCS decisions are discussed.
6. Coordination of recommended psychosocial treatments or interventions, and assessment of progress

<table>
<thead>
<tr>
<th>Processes and Procedures Related to the Psychosocial Evaluation</th>
</tr>
</thead>
<tbody>
<tr>
<td>• The evaluator should coordinate all intervention activities, or designate another team member.</td>
</tr>
<tr>
<td>• The evaluator should identify who will monitor intervention progress and communicate progress to the team.</td>
</tr>
<tr>
<td>• The evaluator should specify before an intervention is initiated how progress/success will be defined.</td>
</tr>
<tr>
<td>• The evaluator should provide specific criteria (e.g., a time line or clinical benchmarks) indicating when any psychosocial re-evaluation should be performed.</td>
</tr>
</tbody>
</table>
Methods

**Strategies to come to consensus:**

- Synthesis of expert opinion on the **content** of the psychosocial evaluation
- Synthesis of expert opinion on the **processes and procedures** for (a) conducting the evaluation, (b) reporting its results, and (c) implementing any additional testing or treatment
- Literature reviews of empirical evidence to support the Committee’s recommendations regarding **both evaluation content/process**.
Literature Review

- Rigorous and robust
  - Peer reviewed articles (English language only)
  - Focus on adults (≥18 years)
  - Publication dates between 2000 – mid 2017
  - Seminal articles published before 2000
    - as per Writing Committee member recommendations
- Provides strong evidence for both content and process / procedure recommendations
Psychosocial factors at each stage of the transplant & mechanical circulatory support process

Pre-surgical Considerations
- Psychosocial factors affecting access to CT TX and MCS
- Patient preferences and decision-making
- Psychosocial evaluation for CT TX and MCS implant
- Informed consent

CT TX and MCS Surgery

Psychosocial Outcomes During CT TX and MCS Implant
- Patient physical, psychological, social, and global HRQOL
- Patient adherence and self-care
- Family caregiver well-being and QOL
- Economic burdens for the patient and family

Psychosocial Predictors of Clinical Outcomes During CT TX and MCS
- Adverse events
- Survival

Post-operative and End of Life Considerations
- Post-operative Outcomes
  - Patient HRQOL after surgery
  - Patient HRQOL after recovery
- End of Life Issues
  - Patient preferences and decision-making
  - Family concerns
  - Symptom management and palliative care choices

CT = cardiothoracic; TX = transplant; MCS = mechanical circulatory support; HRQOL = health-related quality of life

Grady KL & Dew MA, from Braunwald E, MCS Companion to Heart Disease, 2017 (modified)
Informed Consent

• Informed consent is a process, not an event, followed by documentation of that process (i.e., signing of a consent form)

• 4 basic elements:
  – (1) decision-making capacity of the patient or surrogate
  – (2) disclosure of sufficient details of the proposed treatment by the physician
  – (3) demonstration of understanding of the disclosed information by the patient or surrogate
  – (4) voluntary agreement to the treatment

Importantly, this process is patient-centric
Informed consent is a process

Includes informing patients about:
- Current medical condition and natural history
- Prognosis re both quantity and quality of life re options
- Risks and benefits of therapeutic options
- Uncertainty
- Need for self-care of therapeutic options
- Effect on lifestyle
- Costs
- Caregiver burden
- End-of-life considerations with each therapeutic option

Includes understanding the patients preferences, values and goals

Grady K & Dew MA. In MCS, A Companion to Braunwald’s Heart Disease, 2012
The pre-surgical time period is a critical time consisting of referral, shared decision making, evaluation, and informed consent.

Evaluation for cardiothoracic transplantation and mechanical circulatory support must be thorough and processes must be based on best practices.

Only then, can potential candidates for advanced surgical therapies provide truly informed consent.
“Thoracic organ transplantation improves the length and quality of life of patients with severe heart or lung disease. It is a societal endeavor bound by ethical principles.”